Quantcast

Latest hemophilia A Stories

2014-06-23 08:27:25

LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. "Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-04-16 16:26:40

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022SummaryThe competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of...

2014-02-20 08:30:34

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 EpiCast Report: Hemophilia - Epidemiology Forecast to 2022 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of...

2014-02-18 04:21:07

- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb. 18, 2014 /PRNewswire/ -- Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company's investigational long-acting site-specific PEGylated recombinant human factor VIII compound BAY 94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the...

2013-09-24 23:27:47

Global Hemophilia Market Report: 2013 Edition research studies the hemophilia market on a global scale and its various segments. Dallas, Texas (PRWEB) September 24, 2013 The key trends observed within the global hemophilia market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related